Humacyte clinical trials we track

Check company identity source

Phase 3 3 trials

Phase 2 / 3 1 trial

Phase 2 2 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: ATEV Primary Patency - Extremity Group (Non-iatrogenic) Measure: Rate of ATEV Infection - Extremity Group (Non-iatrogenic) Measure: Number of Participants With Adverse Events for Each Severity Grade - Extremity Group (Non-iatrogenic). After: Measure: Primary Patency Rate of the Human Acellular Vessel (HAV) at Day 30 in the All HAV Group Measure: Primary Patency Rate of the Human Acellular Vessel (HAV) at Day 30 in the Extremity Community-Acquired Trauma Subgroup.

Actual enrollment increased by 21 participants

Before: 51 participants (actual). After: 72 participants (actual).

Primary completion date changed

Before: 30 Jun 2023. After: 19 Sep 2023.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 4 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 150 participants (planned). After: 121 participants (actual).

Primary completion date changed

Before: Oct 2026. After: Jun 2027.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source